We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Original Investigation |

Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder A Randomized Clinical Trial

Evdokia Anagnostou, MD1,2; Michael G. Aman, PhD3; Benjamin L. Handen, PhD4; Kevin B. Sanders, MD5; Amy Shui, MA6; Jill A. Hollway, PhD3; Jessica Brian, PhD1,2; L. Eugene Arnold, MD3; Lucia Capano, MD1,2; Jessica A. Hellings, MD3; Eric Butter, PhD7,8; Deepali Mankad, MD1,2; Rameshwari Tumuluru, MD4; Jessica Kettel, MD4; Cassandra R. Newsom, PsyD9; Stasia Hadjiyannakis, MD10; Naomi Peleg, MSc1; Dina Odrobina, BMSc1; Sarah McAuliffe-Bellin, MEd4; Pearl Zakroysky, MPH6; Sarah Marler, MA5; Alexis Wagner, BS3; Taylor Wong, BS3; Eric A. Macklin, PhD6,11; Jeremy Veenstra-VanderWeele, MD12,13,14
[+] Author Affiliations
1Bloorview Research Institute, Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada
2Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada
3Nisonger Center, The Ohio State University, Columbus
4Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania
5Department of Psychiatry, Vanderbilt University, Nashville, Tennessee
6Biostatistics Center, Massachusetts General Hospital, Boston
7Department of Psychology, Nationwide Children's Hospital, Columbus, Ohio
8Department of Pediatrics and Psychology, The Ohio State University, Columbus
9Department of Pediatrics, Vanderbilt University, Nashville, Tennessee
10Department of Pediatrics, CHEO Research Institute, University of Ottawa, Ottawa, Ontario, Canada
11Department of Medicine, Harvard Medical School, Boston, Massachusetts
12Department of Psychiatry and Sackler Institute for Developmental Psychobiology, Columbia University, New York, New York
13New York State Psychiatric Institute, New York
14Center for Autism and the Developing Brain, New York Presbyterian Hospital, White Plains, New York
JAMA Psychiatry. 2016;73(9):928-937. doi:10.1001/jamapsychiatry.2016.1232.
Text Size: A A A
Published online

Importance  Atypical antipsychotic medications are indicated for the treatment of irritability and agitation symptoms in children with autism spectrum disorder (ASD). Unfortunately, these medications are associated with weight gain and metabolic complications that are especially troubling in children and with long-term use.

Objective  To evaluate the efficacy of metformin for weight gain associated with atypical antipsychotic medications in children and adolescents with ASD (defined in the protocol as DSM-IV diagnosis of autistic disorder, Asperger disorder, or pervasive developmental disorder not otherwise specified), aged 6 to 17 years.

Design, Setting, and Participants  A 16-week, double-blind, placebo-controlled, randomized clinical trial was conducted at 4 centers in Toronto, Ontario, Canada; Columbus, Ohio; Pittsburgh, Pennsylvania; and Nashville, Tennessee. In all, 209 potential participants were screened by telephone, 69 individuals provided consent, and 61 participants were randomized to receive metformin or placebo between April 26, 2013, and June 24, 2015.

Interventions  Metformin or matching placebo titrated up to 500 mg twice daily for children aged 6 to 9 years and 850 mg twice daily for those 10 to 17 years.

Main Outcomes and Measures  The primary outcome measure was change in body mass index (BMI) z score during 16 weeks of treatment. Secondary outcomes included changes in additional body composition and metabolic variables. Safety, tolerability, and efficacy analyses all used a modified intent-to-treat sample comprising all participants who received at least 1 dose of medication.

Results  Of the 61 randomized participants, 60 participants initiated treatment (45 [75%] male; mean [SD] age, 12.8 [2.7] years). Metformin reduced BMI z scores from baseline to week 16 significantly more than placebo (difference in 16-week change scores vs placebo, −0.10 [95% CI, −0.16 to −0.04]; P = .003). Statistically significant improvements were also noted in secondary body composition measures (raw BMI, −0.95 [95% CI, −1.46 to −0.45] and raw weight, −2.73 [95% CI, −4.04 to −1.43]) but not in metabolic variables. Overall, metformin was well tolerated. Five participants in the metformin group discontinued treatment owing to adverse events (agitation, 4; sedation, 1). Participants receiving metformin vs placebo experienced gastrointestinal adverse events during a significantly higher percentage of treatment days (25.1% vs 6.8%; P = .005).

Conclusions and Relevance  Metformin may be effective in decreasing weight gain associated with atypical antipsychotic use and is well tolerated by children and adolescents with ASD.

Trial Registration  clinicaltrials.gov Identifier: NCT01825798

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?


Place holder to copy figure label and caption
Figure 1.
CONSORT Flow Diagram
Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Metformin Effect on Body Mass Index (BMI) z Score and Weight Change

Estimates of means for the treatment and placebo groups at each visit. Error bars indicate 95% CIs.

aSignificant difference at each visit.

Graphic Jump Location





You need to register in order to view this quiz.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Quick Reference

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Quick Reference